Argenx announces positive chmp opinion for vyvgart (efgartigimod alfa) subcutaneous injection for chronic inflammatory demyelinating polyneuropathy (cidp)

Vyvgart ® is first-and-only targeted igg fc-antibody fragment for cidp first novel mechanism of action for cidp treatment in more than 30 years chmp positive opinion based on adhere data, the largest ever cidp clinical trial european commission (ec) decision on marketing authorization application (maa) expected within approximately two months april 28, 2025, 07:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has recommended european commission (ec) approval of vyvgart® 1000mg (efgartigimod alfa) for subcutaneous (sc) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (cidp) after prior treatment with corticosteroids or immunoglobulins. “our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs.
ARGX Ratings Summary
ARGX Quant Ranking